Alteogen Shifts Revenue Model with Keytruda Qlex Royalties, Secures $1.2 Billion in New Deals
South Korean biotechnology firm Alteogen is moving to a royalty-driven revenue model as Merck & Co. launches Keytruda Qlex, a subcutaneous version of its immunotherapy. Alteogen's ALT-B4 platform, which converts intravenous biologics to subcutaneous formulations, underpins this shift. The company also signed three new licensing agreements this year, totaling up to $1.229 billion in potential value.
Royalty-Driven Growth Emerges
Alteogen, a South Korean firm, shows a shift in its revenue strategy. Its Hybrozyme platform, featuring ALT-B4 (berahyaluronidase alfa), enables the conversion of high-dose intravenous biologics into subcutaneous formulations. With Merck & Co.'s (MSD) launch of Keytruda Qlex in the U.S., Alteogen's income model now includes commercial product royalties.
The U.S. FDA approved Keytruda Qlex in September 2025. MSD reported Keytruda Qlex revenue of $128 million in the first quarter of 2026, rising to $463 million in the second quarter of 2026. MSD attributes this growth to increased physician and patient adoption following a permanent U.S. reimbursement J-code assignment in April 2026.
Alteogen receives a 2 percent royalty on Keytruda Qlex net sales after specific milestones are met, complementing its milestone payments.
Expanding Licensing Portfolio
Alteogen secured three new ALT-B4 licensing agreements this year, potentially valued at up to $1.229 billion. In January 2026, a GSK subsidiary, Tesaro, obtained global exclusive rights to use ALT-B4 for a subcutaneous version of GSK’s PD-1 immunotherapy, Jemperli (dostarlimab). This deal carries a potential value of up to $285 million, including a $20 million upfront payment.
In March 2026, Alteogen signed a deal with Biogen, potentially worth up to $579 million, for two undisclosed biologics. This included a $20 million upfront payment, with an additional $10 million due upon the second product's development start.
A third agreement, announced this week, grants a global pharmaceutical company exclusive rights for one biologic using ALT-B4, valued at up to $365 million in upfront and milestone payments. Royalties on future net sales are separate for all three.
Financial Performance and Asia Outlook
Alteogen's financial performance currently shows volatility. In the first quarter of 2026, the company recorded consolidated revenue of 71.6 billion won and an operating profit of 39.3 billion won. ALT-B4 technology services generated 66.1 billion won, representing 92.3 percent of total sales.
While Alteogen reported 28.1 billion won in product sales last year from commercial ALT-B4 supply, it did not show product sales in the first quarter of 2026. This highlights continued reliance on milestone achievements and production schedules.
For Asian biotech and medical aesthetics companies, Alteogen's trajectory demonstrates the potential for significant revenue generation through platform technology licensing and royalty agreements, particularly for drug delivery innovations.
However, it also shows the challenge of diversifying revenue streams beyond a flagship platform and securing deals comparable in scale to its initial collaboration with MSD.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
